Clinical note · Micronutrient diagnostics
CMA or SpectraCell? Two tests, two different questions.
Both measure nutrient status inside the cell rather than in serum. The difference lies not in the ambition but in the construction — and that determines what the answer can be used for.
Clinical note — methodological comparison, not a marketing claim.
4.8 ★★★★★ out of 5 · 89 reviews on Reco Checked 22 October 2026. Read the full profile and Reco’s labels for individual reviews. Reco.seRead reviewsAbout this text. This is a methodological comparison of two laboratory assays. It states openly that neither assay is established standard diagnostics and that both are assessed similarly by US payers. The comparison concerns construction and resolution, not evidentiary status.
Two tests, two different questions
CMA from Cell Science Systems and SpectraCell’s Micronutrient Test are cell-based functional assays with different experimental designs. CMA examines how added nutrients affect cellular responses in the laboratory. It does not measure the actual amount of a nutrient inside the body’s cells. Results need interpretation alongside diet, symptoms and relevant established laboratory tests.
The similarity ends at how the measurement is made. The two assays ask the cell different questions, and that determines what the answer can be used for.
SpectraCell: depletion in an optimised medium
SpectraCell's method is a lymphocyte proliferation assay of depletion type. The patient's lymphocytes are placed in a culture medium containing optimal levels of all nutrients. A single nutrient is then removed from the medium, and cell growth is measured against growth in the complete medium. Failure to grow is interpreted as insufficient functional status for that nutrient. The panel covers 31 analytes.
The design is internally consistent, but the question it asks is: how do these cells respond when one substance is absent from an otherwise ideal environment? That is not the same as asking how the cells perform in the patient's own environment.
CMA: repletion in the patient's own serum
CMA inverts the design. Lymphocytes are separated from the patient's whole blood and the patient's own serum is added back to the cells. The cells are stimulated with a mitogen and a baseline proliferation rate is recorded — how the patient's cells actually perform in the patient's own biochemical environment. Micronutrients are then added and proliferation is compared against that individual baseline. The panel covers 55 analytes.
Two things separate this from the depletion design. Measurement occurs in autologous serum, meaning the patient's actual milieu — including whatever is insufficient in it — forms part of the test condition rather than being corrected away. And the question asked is the clinically operative one: does cellular function improve if this substance is supplied?
That question translates directly into a treatment decision. A result showing proliferation rising when a nutrient is added is an argument for supplying that nutrient. A depletion result answers an adjacent but different question.
What the differences mean in practice
The analyte count — 55 against 31 — is the simplest difference and the least interesting. The decisive difference is the frame of reference. When the baseline consists of the patient's own cells in the patient's own serum, every result is individually calibrated. The comparison is not against a population mean but against the person themselves.
This matters in precisely the conditions where the test is considered: prolonged fatigue, impaired recovery, suspected metabolic bottleneck. In those cases the question is rarely whether the patient deviates from the population, but whether there is a correctable deficit in this particular person's cellular conditions.
Where both tests stand — without euphemism
This deserves plain statement, and there is nothing to gain by avoiding it: neither assay is established standard diagnostics, and both are assessed similarly by US payers.
Molina's policy on intracellular micronutrient analysis explicitly names SpectraCell, the Cell Science Systems cellular micronutrient assay and ExaTest as not meeting coverage criteria. Blue Cross Blue Shield policies treat intracellular micronutrient analysis as a category and consider it investigational. Neither assay is FDA-approved; both are laboratory-developed tests.
Claiming that CMA falls outside that assessment would be false. What separates the assays is methodological design and resolution — not evidentiary status. Anyone selling intracellular micronutrient analysis as validated routine diagnostics is taking liberties with the evidence.
What does that mean clinically? That the assay is one input among several, not a verdict. We use it when the clinical question has been formulated first, and we read it alongside history, conventional tests and other findings. It does not replace serum testing — it answers a different question than serum testing does.
When each assay is warranted
If the question is whether a nutrient is missing in gross terms, conventional serum testing is cheaper, faster and sufficient. It should be done first. Ferritin, B12, folate, vitamin D and calcium answer most questions that arise in everyday practice.
CMA may contribute information about functional cellular responses to added nutrients where a clinical question justifies the assay. The clinic’s method choice is based on how the result may contribute to the overall assessment. A laboratory response does not itself show whether nutritional support will improve a patient’s symptoms.
That is also why we work with CMA rather than SpectraCell. It is a methodological choice, not a claim that one assay is validated and the other is not.
Frequently asked questions
What is the difference between CMA and SpectraCell's micronutrient test?
Both are cell-based functional assays with different experimental designs. SpectraCell uses a design in which nutrients are omitted from culture medium. CMA compares cellular responses before and after nutrients are added and covers 55 substances according to the laboratory’s panel description. CMA does not measure the actual amount of a nutrient inside the body’s cells.
Why does it matter that CMA uses the patient's own serum?
Because the frame of reference becomes individual. When cells are measured in the patient's own biochemical environment, the patient's actual conditions form part of the test rather than being corrected away by an optimised medium. The question answered is then the clinically operative one: does cellular function improve if this substance is supplied? That answer translates directly into a treatment decision.
Is CMA scientifically validated and approved?
No, not as established standard diagnostics, and this applies to both assays. Molina's policy explicitly names both SpectraCell and the Cell Science Systems cellular micronutrient assay as not meeting coverage criteria, and Blue Cross Blue Shield considers intracellular micronutrient analysis as a category investigational. Neither assay is FDA-approved; both are laboratory-developed tests. The assay is therefore used as one input in an overall clinical assessment, never as a sole basis for decisions.
Does CMA replace ordinary blood tests?
No. Conventional serum tests are cheaper, faster and answer most questions arising in everyday practice. They should be done first. A functional assay adds something only when serum values are normal but the patient still fails to recover — it then answers a different question than the serum test does.
Why does MediBalans use CMA rather than SpectraCell?
It is a methodological choice. The repletion design in autologous serum answers whether supplying a substance improves function in that specific patient, which is the question a treatment decision rests on. The panel is also broader, 55 analytes against 31. This is not a claim that one assay is validated and the other is not — both occupy the same evidentiary position.
Sources
- Molina Healthcare. Clinical Policy: Intracellular Micronutrient Analysis (G2099) — names SpectraCell, the Cell Science Systems cellular micronutrient assay and ExaTest.
- Blue Cross Blue Shield, FEP Medical Policy 2.04.73 — Intracellular Micronutrient Analysis. Bedöms som investigational.
- Cell Science Systems. Cellular Nutrition Assays — method description: lymphocytes in autologous serum, mitogen stimulation, baseline proliferation and repletion.
- SpectraCell Laboratories. Micronutrient Test — metodbeskrivning: lymfocytproliferationsanalys med depletion ur optimerat medium.
Measurement before interpretation
Which assay is warranted depends on the clinical question — and conventional tests should be done first. An initial consultation determines what actually adds something.
Keep reading. Explore symptom guides, clinical notes, assessments and diagnostics in our knowledge base.
Visit the knowledge base →MediBalans + Meet Mario
Your plan continues between visits
For patients following a MediBalans protocol, Meet Mario can make the plan easier to follow between visits, with a meal plan, educational explanations and a separate channel to the care team.
See how Meet Mario supports your plan